| 阚璇 翟兴鹏 王悦申 赵新茹 牛作兴.原发性乳腺淋巴瘤研究进展[J].,2016,16(7):1386-1389 |
| 原发性乳腺淋巴瘤研究进展 |
| Advances in Primary Breast Lymphoma |
| |
| DOI： |
| 中文关键词: 原发性乳腺淋巴瘤 隆胸 进展 |
| 英文关键词: Primary breast lymphoma Breast implants Advances |
| 基金项目: |
|
| 摘要点击次数: 738 |
| 全文下载次数: 0 |
| 中文摘要: |
| 原发性乳腺淋巴瘤（primary breast lymphoma，PBL)是一种罕见的结外型淋巴瘤，最常见的病理类型为弥漫大B 细胞淋巴
瘤，近年来隆胸相关的间变大细胞淋巴瘤亦被界定为新的临床类型。其与乳腺癌相比，临床表现和影像学检查均无特异性，需依
靠病理活检及免疫组化明确诊断，预后较差。目前PBL尚无标准治疗方案，但趋向于以环磷酰胺+阿霉素+ 长春新碱+泼尼松
（cyclophosphamide+doxorubicin+vincristine +prednisolone，CHOP）方案化疗为主的综合治疗方案, 避免采用扩大的手术治疗。 |
| 英文摘要: |
| Primary breast lymphoma（PBL) is a rare form of extranodal lymphoma. The most common histologic subtypes of
PBL isthe diffuse large B-cell lymphoma and recently primary breast anaplastic large cell lymphoma associated with breast implants considered
as a new clinical entity of PBL. Compared with breast cancer, its clinical presentation and imaging have no specialty, the majority
of PBL are diagnosed by pathological biopsy or immunohistochemical analysis and its prognosis is poor. There is no standard therapy
regimen of PBL up to now. The combined therapy regimen, the main part of which is cyclophosphamide in combination with doxorubicin,
vincristine, prednisolone(CHOP) chemotherapy, is the main stream. Radical surgery is to be avoided. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
